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At present no successful treatment is available for advanced thyroid cancer, which com-
prises poorly differentiated, anaplastic, and metastatic or recurrent differentiated thyroid
cancer not responding to radioiodine. In the last few years, biologically targeted therapies
for advanced thyroid carcinomas have been proposed on the basis of the recognition of
key oncogenic mutations. Although the results of several phase II trials look promising,
none of the patients treated had a complete response, and only a minority of them had a
partial response, suggesting that the treatment is, at best, effective in stabilizing patients
with progressive disease. “Epigenetic” refers to the study of heritable changes in gene
expression that occur without any alteration in the primary DNA sequence.The epigenetic
processes establish and maintain the global and local chromatin states that determine
gene expression. Epigenetic abnormalities are present in almost all cancers and, together
with genetic changes, drive tumor progression.Various genes involved in the control of cell
proliferation and invasion (p16INK4A, RASSF1A, PTEN, Rap1GAP, TIMP3, DAPK, RARβ2,
E-cadherin, and CITED1) as well as genes speciﬁc of thyroid differentiation (Na+/I− sym-
port, TSH receptor, pendrin, SL5A8, and TTF-1) present aberrant methylation in thyroid
cancer. This review deals with the most frequent epigenetic alterations in thyroid cancer
and focuses on epigenetic therapy, whose goal is to target the chromatin in rapidly dividing
tumor cells and potentially restore normal cell functions. Experimental data and clinical
trials, especially using deacetylase inhibitors and demethylating agents, are discussed.
Keywords: advanced thyroid cancer, anaplastic thyroid cancer, target therapy, epigenetic, histone deacetylase
inhibitors, demethylating agents
INTRODUCTION
Thyroid carcinoma is the most common endocrine malignancy
worldwide, its incidence being approximately 1–5% of all can-
cers in females and less than 2% in males. Even though it is
considered a relatively rare neoplasm, its incidence is progres-
sively increasing (Kilfoy et al., 2009). Thyroid carcinomas arising
from follicular epithelial cells (about 95% of all thyroid tumors)
are traditionally classiﬁed as well-differentiated thyroid carcino-
mas (WDTC), including both papillary (PTC, 80%) and follicular
types (FTC, 10–15%; Fassnacht et al., 2009), poorly differenti-
ated thyroid carcinomas (PDTC; Patel and Shaha, 2006; Ghossein,
2009) and, ﬁnally, anaplastic thyroid carcinoma (ATC), account-
ing for 1–2% of thyroid malignancies. WDTC usually share slow
growth rate and high percent of cure achieved by a combination
of surgery, radioiodine ablation, and TSH-suppressive therapy.
Poorly differentiated tumors, either from the beginning or loosing
differentiation as disease progresses, as well as ATC, are generally
resistant to conventional therapies, and no successful treatment is
now available (Smith et al., 2009; Catalano et al., 2010; Sherman,
2011). Medullary thyroid carcinoma (MTC) represents a minority
of thyroid cancers arising from para-follicular calcitonin pro-
ducing cells. Neuroendocrine-derived MTC is not responsive to
either radioiodine or TSH suppression and its treatment is mainly
based on surgery for primary and regional metastatic disease. The
outcome of patients with metastatic disease is similar to that of
radioiodine-unresponsive WDTC (Roman et al., 2006).
The term advanced thyroid cancer refers to all thyroid tumors
resistant to conventional therapies, and comprises PDTC, ATC,
and metastatic or recurrent differentiated cancers which do not
respond to radioiodine. Chemotherapy is generally taken into con-
sideration only for patients with symptomatic or rapidly progres-
sive metastatic disease unresponsive to or unsuitable for surgery,
radioiodine, and external beam radiotherapy; but the efﬁcacy of
cytotoxic systemic chemotherapies for these tumors is fairly poor,
response rates being around 25% or less (Sherman, 2010).
In the recent past, biologically targeted therapies for advanced
thyroid carcinomas have been proposed on the basis of the
recognition of key oncogenic mutations, but also of adaptation
processes facilitating tumor growth, such as hypoxia-inducible
angiogenesis or epigenetic modiﬁcations of chromosomal DNA
and histones.
As far as oncogenes are concerned, RAS mutation may be an
early step in thyroid tumorigenesis, as it is present with frequencies
ranging from 24 to 53% in follicular adenomas (FA) and from 18
to 52% in FTC (Nikiforova et al., 2003a). In FTC, PAX8–PPARγ
rearrangement was also reported (Kroll et al., 2000). RET/PTC
rearrangement, distinctive of PTC, has not been identiﬁed in
FA or FTC, supporting divergent tumor induction/progression
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FIGURE 1 | Main genetic alterations and related epigenetic
modifications in thyroid cancer.
(Wreesmann and Singh, 2008). The majority of PTC, in fact,
are initiated by well characterized genetic events, involving single
activating somatic mutation of BRAF or RAS, and translocations
producing RET/PTC oncogenes (Fagin, 2004). BRAFV600E muta-
tion, found in approximately 40% of PTC (Ciampi and Nikiforov,
2005), leads to constitutively active BRAF and subsequent activa-
tion of the RET/RAS/BRAF/MAPK signal transduction pathway
and, in addition, the presence of BRAF mutations is associated
with decreased expression of mRNAs for the sodium iodide sym-
porter (NIS) and the TSH receptor, that are considered markers of
thyroid differentiation (Durante et al., 2007; Figure 1). Mutated
BRAF is also associated with the PTC to PDTC progression, since
it makes thyroid cells sensitive to TGFβ-induced EMT (epithelial–
mesenchymal transition; Knauf et al., 2011) and it is involved
in the control of some ECM non-cellular components such as
thrombospondin-1; it was reported that BRAFV600E knock-down
caused a reduction of in TSP-1 expression and, as a consequence,
of adhesion and migration/invasion of human thyroid cancer cells
(Nucera et al., 2010, 2011). Moreover, treatment of mice carrying
BRAFV600E PTC with BRAF inhibitors reduced tumor prolifera-
tive index and partially restored thyroid-speciﬁc gene expression
(Chakravarty et al., 2011). Finally, in PTC the pro-angiogenic
factor vascular endothelial growth factor (VEGF) expression cor-
relates with a higher risk of metastasis and recurrence, a shorter
disease-free survival, and BRAF mutation status (Lennard et al.,
2001; Jo et al., 2006).
Poorly differentiated thyroid carcinomas and ATC have a more
complex and less distinct gene proﬁle and molecular data sug-
gest that these aggressive forms may dedifferentiate from WDTC.
For instance, the well-known mutations of BRAF and RAS occur-
ring in PTC are present in more than 50% of PDTC (Ghossein,
2009). In about one-third of anaplastic carcinomas,probably those
arisen from pre-existing PDTC, is present the BRAFV600E muta-
tion (Nikiforova et al., 2003b). It was also suggested that ATC
might develop from RAS-mutated FTC since RAS mutation was
also detected in 6–50% of ATC (Smallridge et al., 2009). Fur-
ther, in ATC a mutation of PI3KCA gene causing Akt and ERK
activation was reported (Smallridge et al., 2009). Additional muta-
tions frequently observed in ATC involve p53 and β-catenin. The
tumor-suppressor gene p53 is fundamental for the progression
from indolent to aggressive thyroid cancer. The inactivating p53
mutation, seldom detected in WDTC, is found in about 55% of
PDTC and ATC (Smallridge et al., 2009). Membrane β-catenin
expression is progressively reduced with loss of tumor differenti-
ation, resulting in tumor invasiveness, and increasing metastatic
potential (Garcia-Rostan et al., 2001).
As far as MTC is concerned, heritable germ-line activating
mutations in RET are found in almost all familial cases and iden-
tical somatic mutations in sporadic disease. Activated RET mutant
proteins also enhance MAPK signaling (Santoro et al., 1995).
The use of selective inhibitors of activated BRAF, RET, and
RET/PTC kinases as well as of VEGF and VEGF receptor to treat
advanced thyroid cancer is under thoughtful evaluation. To date, a
number of clinical trials regarding tyrosine kinase and angiogenic
factors inhibitors are in progress12.
EPIGENETIC ALTERATIONS
In the early 1940s,Conrad HalWaddington coined the term epige-
netics as“the causal interactions between genes and their products,
which bring the phenotype into being” (Waddington, 1942). Cur-
rently, epigenetic refers to the study of heritable changes in gene
expression that occur without any alteration in the primary DNA
sequence (Sharma et al., 2010). The epigenetic processes estab-
lish and maintain the global and local condensed or decondensed
chromatin states that determine gene expression. The continuous
interplay of all these processes is today called “epigenome” –
the epigenetic status that determines the way a single eukaryotic
genome may manifest in different cell types and developmental
stages and that, if aberrant, gives rise to cancer and other diseases.
In fact, epigenetic abnormalities are present in almost all can-
cers and, together with genetic changes, drive tumor progression.
Moreover, acting in concert with genetic changes, they play a role
in the earliest steps of tumorigenesis (Feinberg et al., 2006), as also
suggested by the growing list of tumor-suppressor genes that are
often epigenetically silenced but rarely genetically mutated in the
pre-invasive stages of many cancers (Jones and Baylin, 2007).
Epigenetic information that fulﬁlls the requirement of heri-
tability can be classiﬁed into three distinct types: DNA methyla-
tion, histone modiﬁcations, and non-coding RNAs.
In the present review, we will primarily discuss DNA methy-
lation, and histone modiﬁcations (Figure 2), as drugs that
target these epigenetic modiﬁcations are already at a clinical
developmental stage.
DNA methylation takes place within the CpG dinucleotides,
and its consequence is the silencing of genes and non-coding
genomic regions. There are three main DNA methyltransferases
(DNMTs): DNMT1, which maintains the existing methylation
patterns followingDNAreplication, andDNMT3AandDNMT3B,
which target previously unmethylated CpGs. Cancer genome
1www.thyroid.org
2www.clinicaltrials.gov
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FIGURE 2 | Nucleosome structure and main epigenetic alterations in
cancer.
is typically characterized by global hypomethylation concomi-
tant with hypermethylation of CpG islands in the promoters of
genes that play important roles in regulating cell cycle, apoptosis,
differentiation, and cell adhesion (Baylin and Herman, 2000).
Post-translational modiﬁcations of the N-terminal tails of his-
tones include acetylation, methylation, phosphorylation, ubiqui-
tination, SUMOylation, and ADP ribosylation. Histone modiﬁca-
tions can lead to either gene activation or repression, depend-
ing upon which residues are modiﬁed and the type of modi-
ﬁcation (Chi et al., 2010). Overall, histone modiﬁcations affect
chromatin conformation and consequently inﬂuence gene tran-
scription, DNA repair and replication, and cell cycle checkpoints
(Sawan et al., 2008). Histone acetylation and deacetylation cause
activation and arrest of gene transcription, respectively, and the
enzymes that catalyze these changes, histone acetyltransferases
(HATs) and histone deacetylases (HDACs), can also target non-
histone proteins such as p53, Hsp90, and α-tubulin (Sterner and
Berger, 2000). There are four classes of HDACs: class I consists
of HDAC 1, 2, 3, and 8; class II consists of HDAC 4, 5, 6, 7, 9,
and 10; class III are sirtuins (SIRT 1–7); and class IV consisting of
HDAC 11. Alterations in histone modiﬁcations signiﬁcantly con-
tribute to the onset and progression of cancer (Chi et al., 2010).
The most common epigenetic modiﬁcations of histones in cancer
are acetylation andmethylation; reduction inmonoacetylatedH4-
K16 and trimethylation of H4-K20 are general features of cancer
cells (Fraga et al., 2005). Altered expression of HDACs has been
Table 1 | Epigenetic modifications in thyroid cancer.
Gene Reference
Genes involved in con-
trol of proliferation and
invasion
p16INK4A Elisei et al. (1998)
RASSF1A Schagdarsurengin et al.
(2002)
PTEN Alvarez-Nuñez et al. (2006)
Rap1GAP Zuo et al. (2010)
TIMP3 Hoque et al. (2005), Hu
et al. (2006)
DAPK
RARβ2
E-cadherin Graff et al. (1998),Wiseman
et al. (2006)
CITED1 Sassa et al. (2011)
Thyroid-speciﬁc genes Na+/I− symport Xing (2007a), Xing (2007b)
TSH receptor
pendrin
SL5A8
TTF-1 Kondo et al. (2009)
reported in tumor samples; overexpression of class I HDACs has
been reported in 5–40% of cancer tissues (Nakagawa et al., 2007),
HDAC1 is overexpressed in prostate, gastric, colon, and breast
carcinomas. HDAC2 is overexpressed in colorectal, cervical, and
gastric cancer, whereas overexpression of HDAC6 is observed in
breast cancer specimens (Ellis et al., 2009).
MicroRNAs (miRs), are small (19–25 nucleotides), non-coding
RNA molecules representing the most recent class of molecules
known to be involved in epigenetic regulation. They function as
negative regulators of the expression of protein-encoding genes,
involved in major processes such as development, apoptosis, cell
proliferation, immune response, and hematopoiesis.
EPIGENETIC MODIFICATIONS IN THYROID CANCER
Various genes involved in the control of cell proliferation and inva-
sion aswell as genes speciﬁc of thyroid differentiation are epigenet-
ically silenced in thyroid cancer (Table 1). Cumulative epigenetic
alterations play a role in the sequential progression from indo-
lentWDTC to metastasizing carcinomas, through the spectrum of
poorly differentiated to undifferentiated thyroid carcinoma.
DNA METHYLATION
In thyroid cancer,aberrantmethylationof tumor-suppressor genes
is common. CDK inhibitors, such as p27KIP1 and p16INK4A,
are commonly down-regulated; methylation of CpG islands in
p16INK4A is detected in 30% of thyroid neoplasms (Elisei et al.,
1998).
The tumor-suppressive Ras effector, RAS association domain
family 1, splicing isoform A (RASSF1A) contains a Ras association
domain, and plays a role in the regulation of cell cycle and apop-
tosis (Donninger et al., 2007). In the thyroid, RASSF1A promoter
methylation is present in more than 30% of benign and malignant
thyroid tumors. The high frequency of RASSF1A hypermethyla-
tion both in benign FA (33–44%) and the increased occurrence in
FTC (70–100%) suggest that epigenetically silencing of RASSF1A
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is an early step in thyroid tumorigenesis (Schagdarsurengin et al.,
2002).
PTEN, a phosphatase that terminates the PI3K/Akt pathway,
has been found aberrantly methylated in about 50% of papillary
carcinomas and almost 100% of follicular carcinomas and adeno-
mas, suggesting that it may be involved in thyroid tumorigenesis
(Alvarez-Nuñez et al., 2006).
Rap1GAP is a Rap1 GTPase-activating protein that inhibits the
RAS superfamily protein Rap1 by facilitating hydrolysis of GTP to
GDP. In human thyroid cancers,Rap1GAPexpression is frequently
lost or down-regulated secondary to promoter hypermethyla-
tion and/or loss of heterozygosity; Rap1GAP loss of expression
correlates with tumor invasiveness (Zuo et al., 2010).
A close association between BRAF mutation and aberrant
methylation of several tumor-suppressor genes in PTC, includ-
ing the genes for tissue inhibitor of matrix metalloproteinase-3
(TIMP3), death-associated protein kinase (DAPK), and retinoic
acid receptor β2 (RARβ2) has been reported (Hoque et al.,
2005). This association correlatedwith high-risk clinicopathologi-
cal characteristics of PTC, including extra-thyroid invasion, lymph
node metastasis, and advanced disease stages (III and IV; Hu et al.,
2006). TIMP3 suppresses tumor growth, angiogenesis, invasion,
and metastasis both by preventing the interstitial matrix destruc-
tion promoted by matrix metalloproteinase (MMP)-3 and by
blocking the binding of VEGF to the VEGF receptor (Anand-Apte
et al., 1996). Therefore, methylation-mediated silencing of the
TIMP3 gene may play a unique role in BRAF mutation-promoted
invasiveness and progression of PTC.
As far as invasiveness is concerned, E-cadherin joins together
with catenins to promote Ca2+-dependent, homotypic cell-to-
cell adhesion and to establish normal epithelial tissue architec-
ture. Disruption of the E-cadherin/catenin complex contributes
to tumor metastasis, and decreased expression of E-cadherin is
observed in advanced stage, poorly differentiated carcinomas,
(Graff et al., 1998) and is associated with the transformation of
differentiated into ATC (Wiseman et al., 2006).
Aberrant methylation also involves thyroid-speciﬁc genes such
as the Na+/I− symporter (NIS), the promoter of the TSH receptor,
the genes for the putative thyroid follicular cell apical iodide trans-
port (pendrin and SCL5A8; Xing 2007a,b). Suppression of these
thyroid iodide-metabolizing molecules results in the loss of cancer
cells ability to concentrate iodine, rendering tumors insensitive to
radioiodide therapy.
Hypomethylation of the CpGs in the promoter region of
CITED1 (Cbp/p300 InteractingTransactivatorswith glutamic acid
[E] and aspartic acid [D]-rich C-terminal domain) is associated
with higher expression of CITED1 mRNA in PTC tissues (Sassa
et al., 2011).
HISTONE MODIFICATIONS
Unfortunately, little information about the histone modiﬁcations
present in thyroid tumors and the relationship between such
modiﬁcations and thyroid cancer behavior is at present available.
However, recently, Puppin et al. (2011) investigated whether
global levels of acetylated histones are modiﬁed in thyroid can-
cer tissues. They show that levels of acetylated H3 at residue K18
are lower in undifferentiated cancers with respect to differentiated
Table 2 | Epigenetic drugs in clinical trials for the treatment of
advanced thyroid cancer (www.clinicaltrials.gov and
https://oss-sper-clin.agenziafarmaco.it).
Drug Epigenetic target Developmental
stage
Decitabine DNMT Phase II
Depsipeptide HDAC1,2 Phase I/II
Vorinostat (SAHA) HDACs (class I, IIa, IIb, IV) Phase II
Valproic acid (VPA) HDACs (class I, II) Phase II/III
Panobinostat (LBH589) HDACs (class I, IIa, IIb, IV) Phase II
tumors, suggesting that acetylation is switched off in the thyroid
tumor transition.
CpG hypermethylation in the promoter region of the thy-
roid transcription factor-1 (TTF-1), which is essential for thy-
roid organogenesis, concurrently with increased dimethyl-H3-K9
and decreased acetyl-H3-K9, has been observed in a subset of
thyroid carcinoma cells that had lost TTF-1 expression (Kondo
et al., 2009); moreover, it has recently been demonstrated that the
enhancer of zeste homolog 2 (EZH2), a histone lysine methyl-
transferase belonging to the polycomb group protein family, is
speciﬁcally overexpressed in ATC, and it directly contributes to
transcriptional silencing of PAX8 gene and ATC differentiation
(Borbone et al., 2011).
microRNA
Comparative analysis of miRs expression in normal thyroid tissue
versus neoplastic tissue has shown that, in thyroid neoplasms, 32%
of miRs were up-regulated and 38% were down-regulated; more-
over, miRs expression proﬁles had substantial variability within
speciﬁc tumor types (Nikiforova et al., 2008). Down-regulation of
anti-invasive miR-200 and miR-30 families directs the EMT and
invasive potential of ATCs (Braun et al., 2010). Recently it has been
reported that twohistone deacetylase inhibitors, trichostatinA and
vorinostat, induced miR-129-5p overexpression, histone acetyla-
tion and cell death in papillary, and anaplastic cancer cell lines and
in primary cultures of papillary thyroid cancer (Brest et al., 2011).
EPIGENETIC DRUGS
Epigenetic therapy was conceived to activate genes abnormally
silenced in cancer by epigenetic mechanisms. Epigenetic drugs are
expected to target the two main mechanisms of epigenetic alter-
ations, DNA methylation, and acetylation, controlling though the
differentiation and proliferation of transformed cells. To date, dif-
ferent epigenetic drugs are in clinical trials for the treatment of
advanced thyroid cancer (Table 2).
The possibility of a microRNA-based therapy in cancer, using
these small molecules as both targets and tools, suggests a new
intriguing and promising therapy. Several preclinical studies
underline this possibility; however, as to date no clinical trial is
available, there will be no further discussion in the present review.
DEMETHYLATING AGENTS
During thyroid tumor progression, many speciﬁc thyroid genes
(e.g.,NIS andTSH receptor genes) are hypermethylated and, there-
fore silenced; demethylating agents might reverse the malignant
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cell phenotype. Indeed, it was reported that demethylating agents
like decitabine are able to restore NIS and TSH-R expression in
human thyroid carcinoma cell lines (Venkataraman et al., 1999;
Xing et al., 2003; Provenzano et al., 2007; Tuncel et al., 2007). Fur-
thermore, decitabine treatment suppressed the growth of undif-
ferentiated and dedifferentiated thyroid carcinoma cells (Miasaki
et al., 2008; Vivaldi et al., 2009).
At present, the methyltransferase inhibitors azacitidine and
decitabinehavebeen licensed for clinical therapyonly inmyelodys-
plastic syndrome, but new hypomethylating agents (zebularine
and isothiocyanates) are in various stages of development for can-
cer therapy (Kurkjian et al., 2008). In particular, a phase II clinical
trial is ongoing for treatment with decitabine of patients with
metastatic thyroid cancers unresponsive to radioiodine (see text
footnote 2). The results of the trial, whose primary objective is
to determine whether decitabine can restore iodine 131 uptake
in patients with metastatic papillary thyroid or follicular thyroid
cancer, are expected for June 2012.
HISTONE DEACETYLASE INHIBITORS
Histone acetylation and deacetylation are key events in controlling
gene transcription; histone acetyltransferases (HATs) and histone
deacetylases (HDACs; Kuo andAllis, 1998) catalyze these reactions
and target also non-histone proteins, like transcription factors
(Sterner and Berger, 2000).
HDAC inhibitors (DCI) are looked upon as very promising
agents in tumor treatments since they, targeting multiple tumori-
genic pathways, preferentially kill transformed cells, and are rel-
atively non-toxic toward normal cells (Johnstone, 2002). Several
structural classes of DCI have been identiﬁed, including short-
chain fatty acids such as phenylbutyrate and valproic acid (VPA);
cyclic tetrapeptides such as trapoxinA, cyclic peptides such as dep-
sipeptide (FK228) and apicidin; benzamides such as MS27-275
and CI-994; hydroxamic acids such as suberoylanilide hydroxamic
acid (SAHA), oxamﬂatin, trichostatin A, and the more recently
developed pan-inhibitors LAQ824, PXD101, and LBH589 (Fuino
et al., 2003; Plumb et al., 2003; Atadja, 2009).
In thyroid cancer, depsipeptide, SAHA, valproic acid, and
panobinostat are the main DCI that are under investigation.
Depsipeptide
Depsipeptide (FK228 or FR901228) is a cyclic peptide that inhibits
histone deacetylase activity at nanomolar concentrations (John-
stone, 2002). In SW-1736 cells it stimulates the expression of NIS,
restores iodide uptake (Kitazono et al., 2001), and sensitizes cells to
doxorubicin (Kitazono et al., 2002). The drug used alone inhibits
the growth of a primary culture from ametastatic BRAFV600E pap-
illary tumor; while in combination with paclitaxel, lovastatin, or
geﬁtinib has synergic effects (Copland et al., 2006). p53 gene ther-
apy associated with depsipeptide inhibits the growth of anaplastic
FRO cell line (Imanishi et al., 2002).
There are currently two clinical studies at the National Cancer
Institute (see text footnote 2). The ﬁrst is a phase I trial examining
the safety and tolerability of depsipeptide in patients with solid
tumors, including thyroid cancer, which has recently been com-
pleted; the second is a phase II trial determining the anti-tumor
activity of the drug in patients with progressive recurrent and/or
metastatic non-MTCs that are refractory to radioactive iodine. No
conclusive data from these studies are available at the moment.
Vorinostat
Vorinostat (SAHA) is a hydroxamic acid that, binding directly to
the HDAC catalytic site, inhibits DAC enzymatic activity (Finnin
et al., 1999). SAHA induces growth arrest and caspase-mediated
apoptosis in anaplastic thyroid cancer FRO cells (Mitsiades et al.,
2005). Moreover it sensitizes cells to doxorubicin and inhibits
the proliferation of FRO anaplastic tumors grown in nude mice
(Luong et al., 2006).
In a phase I study on vorinostat in advanced cancers, six patients
with thyroid cancer were recruited; one patient with advanced
papillary tumor exhibited a partial response, while one papillary
thyroid patient showed improvement in the RAI scan post-therapy
(Kelly et al., 2005). Successively, a phase II trial was undertaken to
determine whether SAHA was active in patients with metasta-
tic thyroid cancers who did not respond to standard therapy, but
unfortunately, it concluded that 200mg of vorinostat twice a day
was not a useful treatment for advanced thyroid cancer (Woyach
et al., 2009).
Valproic acid
Valproic acid is a short-chain fatty acid which has been used for
a long time in epilepsy and mood disorder treatment (Blaheta
et al., 2005). More recently its activity as DCI (Göttlicher et al.,
2001; Phiel et al., 2001) as well as its anti-proliferative and pro-
differentiating properties in a variety of hematologic and solid
tumors (Duenas-Gonzalez et al., 2008) were reported.
In the last decade,our laboratorywas very interested in studying
the anti-tumor effects of VPA on undifferentiated thyroid cancer
cells. In 2004 we demonstrated that valproic acid induces NIS
gene expression, NIS membrane localization, and iodide accu-
mulation in poorly differentiated thyroid cancer cells (Fortunati
et al., 2004). We also showed (Catalano et al., 2005) that the drug
is highly effective in suppressing the growth of poorly differen-
tiated thyroid cancer cell lines, inducing apoptosis and cell cycle.
In agreement with our results, Shen et al. (2005) demonstrated
that, also in metastatic follicular cell lines, VPA causes signiﬁcant
growth inhibition. Unfortunately, in ATC cells, the induction of
NISmRNA is not followed by a change in iodide uptake (Fortunati
et al., 2004) and VPA does not induce apoptosis (Catalano et al.,
2006). Taken together, these data indicate that VPA alone is not
effective in anaplastic thyroid cancer; however, we demonstrated
that it enhances the cytotoxicity of doxorubicin in ATC cells and
that the sensitizing effect increased apoptosis and doxorubicin-
induced G2 cell cycle arrest (Catalano et al., 2006). Afterward, it
has been reported that some cell lines employed in those in vitro
studies are of non-thyroid origin (Schweppe et al., 2008); thus,
results obtained using these cell lines need to be regarded with
caution. However in the same studies, cells of assessed thyroid
origin showed a similar behavior.
In line with these ﬁndings, it has been reported that VPA, in
combination with the highest concentration of doxorubicin that
does not induce KAT-18 cell death, efﬁciently induced apoptosis in
KAT-18 cells (Kim et al., 2009). Since someDCI that targetHDAC6
(Zhang et al., 2003), likeVPA, can also haveα-tubulin as a substrate
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and tubulin acetylation is linked to microtubule dynamics and
stability (Matsuyama et al., 2002), the effect of VPA used together
with paclitaxel, a microtubule-targeting drug, were evaluated. The
addition of VPA to paclitaxel signiﬁcantly enhanced the cytosta-
tic and cytotoxic effects of paclitaxel in ATC cells (Catalano et al.,
2007). Beside the in vitro studies, one case of successful treatment
of ATCwith a combination of oralVPA, cisplatin and doxorubicin,
plus external and intra-operative radiation, and surgery has been
reported the patient being alive and disease-free 2 years after diag-
nosis (Noguchi et al., 2009). A phase II trial of VPA in patients with
advanced thyroid cancers of follicular origin is active and currently
recruiting patients at the NCI (see text footnote 2). Moreover, an
Italian multicenter phase II/III clinical trial in patients with undif-
ferentiated thyroid cancer treated with a combination of VPA and
paclitaxel is ongoing3.
Panobinostat
Panobinostat (LBH589) is a hydroxamic acid with potent
inhibitory activity at low nanomolar concentrations against all
classes of HDAC enzymes (pan-DAC inhibitor; Atadja, 2009).
In vitro treatment with LBH589 of three ATC cell lines (BHT-
101, CAL-62, and 8305C) resulted in impairment of cell via-
bility, inhibition of colony formation, cell cycle arrest, and
apoptosis induction. LBH589 markedly determined microtubule
stabilization as evidenced by tubulin acetylation and increased
3https://oss-sper-clin.agenziafarmaco.it
tubulin polymerization. The cytotoxic properties of LBH589 were
conﬁrmed in a SCID xenograft model implanted with CAL-62
cells (Catalano et al., 2011).
A phase II trial of LBH589 in patients with metastatic MTC
and radioactive iodine resistant differentiated thyroid cancer is
now recruiting participants at the NCI (see text footnote 2).
CONCLUDING REMARKS
Epigenetic drugs, that are expected to target the two main mecha-
nisms of epigenetic alterations,DNAmethylation, and acetylation,
are regarded with increasing interest by both endocrinologists and
oncologists. Deﬁnitive results from clinical trials will ultimately
clarify the real effectiveness of epigenetic drugs used alone for
treatment of advanced thyroid cancer. Nowadays, trials that have
been concluded showed that only few patients have a complete
response, suggesting that the treatment is, at best, effective in
stabilizing the progressive disease.
The complexity of crosstalk between protein signaling path-
ways implies that a single signaling inhibitor can only produce
modest effects, and suggests that multiple pathways need to be
inhibited in order to substantially affect thyroid cancer growth. In
this direction, epigenetic drugs used in combination with other
target molecules might signiﬁcantly increase the response rate to
treatment in advanced thyroid cancer, either by relaxing the chro-
matin structure and making it more accessible to the effect of a
DNA targeting drug, or by acting synergistically with anti-mitotic
drugs.
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